Current status of sentinel lymph node mapping and biopsy: Facts and controversies

Oncologist

Volumn 8, Issue 1, 2003, Pages 59-68

  Jakub, James W ^a   Pendas, Solange ^a   Reintgen, Douglas S ^a  

^a Lakeland Regional Cancer Center   (United States)

Author keywords

Breast cancer; Colon cancer; Lymphatic mapping; Melanoma; Sentinel lymph node biopsy

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL PRACTICE; COLON CANCER; DIAGNOSTIC ACCURACY; DNA DETERMINATION; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHATIC MAPPING; LYMPHATIC SYSTEM; LYMPHOSCINTIGRAPHY; MASTECTOMY; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SOLID TUMOR; SURGICAL ANATOMY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MORBIDITY; PENILE NEOPLASMS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0037280208     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-1-59     Document Type: Review

References (72)

1. Sappey M. Injection, preparation et conservation des vaisseaux lymphatiques. These pour le doctorat en medecine, 1843:241.
2. Uren RF, Howman-Giles R, Thompson JF et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res 1994;4:395-399.
3. Godellas CV, Berman CG, Lyman G et al. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. Am Surg 1995;61:97-101.
4. Kamath D, Rapaport D, DeConti R et al. Redefining cutaneous lymphatic flow: the necessity of preoperative lymphoscintigraphy in the management of malignant melanoma. J Fla Med Assoc 1997;84:182-187.
5. Uren RF, Howman-Giles RB, Shaw HM et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993;34:1435-1440.
6. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466.
7. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992;127:392-399.
8. Giuliano AE, Kirgan DM, Guenther JM et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
9. Krag DN, Weaver DL, Alex JC et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-339.
10. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-1822.
11. Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-2260.
12. Heller R, Becker J, Wasselle J et al. Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg 1991;126:1455-1460.
13. Heller R, King B, Baekey P et al. Identification of submicroscopic lymph node metastases in patients with malignant melanoma. Semin Surg Oncol 1993;9:285-289.
14. Wang X, Heller R, VanVoorhis N et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-774.
15. Haddad FF, Reintgen DS. Sentinel lymph node biopsy for melanoma. In: Eric DR, Whitman D, eds. Surgical Technique. Radioguided Surgery. Austin: Landed Bioscience, 1999:70.
16. Shaw HM, McCarthy WH, McCarthy SW et al. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147-1150.
17. Slingluff Jr CL, Vollmer RT, Reintgen DS et al. Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 1988;208:150-161.
18. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
19. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
20. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
21. Shivers SC, Wang X, Li W et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-1415.
22. Dessureault S, Soong SJ, Ross MI et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001;8:766-770.
23. Finck SJ, Giuliano AE, Mann BD et al. Results of ilioinguinal dissection for stage II melanoma. Ann Surg 1982;196:180-186.
24. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162-166.
25. Puleo C, Cruse CW, Lowe J. Re-definition of pelvic cutaneous lymphatic drainage based on lymphatic mapping principles. Melanoma Res 2001;11(suppl 1):S104.
26. Karakousis CP, Emrich LJ, Driscoll DL et al. Survival after groin dissection for malignant melanoma. Surgery 1991;109:119-126.
27. McMasters KM, Wong SL, Chao C et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001;234:292-300.
28. Cox CE, Salud CJ, Cantor A et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593-600.
29. Cox CE, Dupont E, Whitehead GF et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J 2002;8:88-91.
30. Wong SL, Edwards MJ, Chao C et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg 2001;192:684-691.
31. McMasters KM, Wong SL, Martin 2nd RC et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001;233:676-687.
32. Kern KA. Lymphoscintigraphic anatomy of sentinel lymphatic channels after subareolar injection of Technetium 99m sulfur colloid. J Am Coll Surg 2001;193:601-608.
33. Halsted WS. A clinical and histological study of certain adenocarcinoma of the breast. Ann Surg 1898;28:557.
34. Greene FA, Page DL, Fleming ID et al. AJCC Cancer Staging Manual. New York: Springer-Verlag, 2002:223-233.
35. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1959;46:574-582.
36. Veronesi U, Cascinelli N, Greco M et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985;202:702-707.
37. Ege GN, Clark RM. Internal mammary lymphoscintigraphy in the conservative management of breast carcinoma: an update and recommendations for a new TNM staging. Clin Radiol 1985;36:469-472.
38. Cox CE, Nguyen K, Gray RJ et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513-521.
39. Burak Jr WE, Owens KE, Tighe MB et al. Vacuum-assisted stereotactic breast biopsy: histologic underestimation of malignant lesions. Arch Surg 2000;135:700-703.
40. Lee CH, Carter D, Philpotts LE et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 2000;217:466-470.
41. Klauber-DeMore N, Tan LK, Liberman L et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7:636-642.
42. Darling ML, Smith DN, Lester SC et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by largecore needle breast biopsy: results of surgical excision. AJR Am J Roentgenol 2000;175:1341-1346.
43. Renshaw AA. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Arch Pathol Lab Med 2002;126:39-41.
44. Lopez MJ, Porter KA. The current role of prophylactic mastectomy. Surg Clin North Am 1996;76:231-242.
45. Dupont EL, Kuhn MA, McCann C et al. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 2000;180:274-277.
46. Kamath VJ, Giuliano R, Dauway EL et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688-692.
47. Chu KU, Turner RR, Hansen NM et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-541.
48. Turner RR, Chu KU, Qi K et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000;89:574-581.
49. Rahusen FD, Torrenga H, van Diest PJ et al. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg 2001;136:1059-1063.
50. Jakub J, Diaz N, Ebert M et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives in patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg 2002;184:302.
51. Pendas S, Dauway E, Cox CE et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65:500-506.
52. Turner RR, Ollila DW, Krasne DL et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-278.
53. Sabel MS, Zhang P, Barnwell JM et al. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol 2001;77:243-246.
54. Turner RR, Giuliano AE, Hoon DS et al. Pathologic examination of sentinel lymph node for breast carcinoma. World J Surg 2001;25:798-805.
55. Greenson JK, Isenhart CE, Rice R et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-569.
56. Liefers GJ, Cleton-Jansen AM, van de Velde CJ et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-228.
57. Rosenberg R, Hoos A, Mueller J et al. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Br J Cancer 2000;83:1323-1329.
58. Jeffers MD, O'Dowd GM, Mulcahy H et al. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994;172:183-187.
59. Cutait R, Alves VA, Lopes LC et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-920.
60. Merrie AE, van Rij AM, Phillips LV et al. Diagnostic use of the sentinel node in colon cancer. Dis Colon Rectum 2001;44:410-417.
61. Bilchik AJ, Nora D, Tollenaar RA et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer 2002;38:977-985.
62. Tsioulias GJ, Wood TF, Spirt M et al. A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy. Am Surg 2002;68:561-565.
63. Paramo JC, Summerall J, Poppiti R et al. Validation of sentinel node mapping in patients with colon cancer. Ann Surg Oncol 2002;9:550-554.
64. Feig BW, Curley S, Lucci A et al. A caution regarding lymphatic mapping in patients with colon cancer. Am J Surg 2001;182:707-712.
65. Bendavid Y, Latulippe JF, Younan RJ et al. Phase I study on sentinel lymph node mapping in colon cancer: a preliminary report. J Surg Oncol 2002;79:81-85.
66. Waters GS, Geisinger KR, Garske DD et al. Sentinel lymph node mapping for carcinoma of the colon: a pilot study. Am Surg 2000;66:943-946.
67. Saha S, Wiese D, Badin J et al. Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. Ann Surg Oncol 2000;7:120-124.
68. Joosten JJ, Strobbe LJ, Wauters CA et al. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg 1999;86:482-486.
69. Noguchi M. Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients. J Surg Oncol 2001;76:144-156.
70. Dessureault S, Soong SJ, Ross MI et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001;8:766-770.
71. Shivers SC, Wang X, Li W et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-1415.
72. Bilchik AJ, Nora D, Tollenaar RA et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer 2002;38:977-985.